AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.[2]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C18H26N4O2 |
Molar mass | 330.432 g·mol−1 |
3D model (JSmol) |
|
| |
|
It was originally developed by Pfizer in 2009 as an analgesic medication.[3][4]
AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 1.5x more potent.[5][6]
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.[7][8]
AB-PINACA is an Anlage II controlled substance in Germany as of November 2014.[9]
It is listed in the Fifth Schedule of the Misuse of Drugs Act and so is illegal in Singapore, as of May 2015.[10]
It is a Schedule I controlled substance in the United States.[11]
It is a controlled substance in China as of October 2015.[12]
It is a controlled substance in France as of March 2017.[13]